- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| RENOVORX Aktie jetzt für 0€ handeln | |||||
| Di | RenovoRx, Inc.: RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer | 2 | GlobeNewswire (USA) | ||
| 21.08. | RenovoRx regains Nasdaq compliance | 1 | Seeking Alpha | ||
| 21.08. | RenovoRx regains Nasdaq minimum bid price compliance | 1 | Investing.com | ||
| 21.08. | RenovoRx erfüllt wieder NASDAQ-Mindestkursanforderung | 2 | Investing.com Deutsch | ||
| 21.08. | RenovoRx, Inc.: RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | 180 | GlobeNewswire (Europe) | MOUNTAIN VIEW, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and... ► Artikel lesen | |
| 20.08. | RenovoRx, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.08. | RenovoRx receives U.S. patent allowance for cancer device | 4 | Investing.com | ||
| 20.08. | RenovoRx, Inc.: RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment | 243 | GlobeNewswire (Europe) | MOUNTAIN VIEW, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and... ► Artikel lesen | |
| 13.08. | RenovoRx, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 12.08. | RenovoRx, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 11.08. | RenovoRx, Inc.: RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer | 1.160 | GlobeNewswire (Europe) | MOUNTAIN VIEW, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and... ► Artikel lesen | |
| 11.08. | EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027 | 1 | Benzinga.com | ||
| 06.08. | RenovoRx, Inc.: RenovoRx Announces First Commercial Clinical Use of RenovoCath in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors | 262 | GlobeNewswire (Europe) | MOUNTAIN VIEW, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and... ► Artikel lesen | |
| 04.08. | RenovoRx, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.06. | RenovoRx, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 30.06. | RenovoRx, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.05. | RenovoRx Says FDA Grants Orphan Drug Status For Oxaliplatin To Treat Pancreatic Cancer | 1 | RTTNews | ||
| 28.05. | RenovoRx, Inc.: RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer | 545 | GlobeNewswire (Europe) | MOUNTAIN VIEW, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing... ► Artikel lesen | |
| 26.05. | RenovoRx, Inc.: RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP Platform Presented at the 2026 ASCO Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 19.05. | RenovoRx, Inc.: RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th | 1 | GlobeNewswire (USA) |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,30 | +0,11 % | BioNTech Aktie: Im Rausch der Moderna-Euphorie - Doch wie lange hält die Party an? | © Foto: von fernando zhiminaicela auf Pixabay (Symbolbild)Fast 30 Prozent in einer einzigen Woche. Das ist lange her, dass sowas bei BioNTech vorkam. Zuletzt wohl zu Pandemie-Zeiten ging es mal so zur... ► Artikel lesen | |
| MODERNA | 119,06 | -0,03 % | Moderna Aktie: Was für ein Wahnsinn bei Moderna! Kippt aber jetzt die Stimmung?! | © Foto: Finanznachrichten (Symbolbild wurde mit KI erstellt)Erst ein Kurssprung wie ihn kaum eine Aktie je erlebt hat, dann der schnelle Absturz, aber kommt jetzt wieder eine Erholung? Moderna sorgt... ► Artikel lesen | |
| NOVAVAX | 7,950 | -0,62 % | Novavax announces regulatory approvals for updated COVID shot | ||
| BIOGEN | 187,62 | -0,51 % | Veeva Systems: Veeva Vault CRM Selected by Biogen | Unified commercial platform to help speed the delivery of medicines to patientsPLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Biogen has... ► Artikel lesen | |
| ILLUMINA | 186,64 | +0,27 % | $100 Invested In Illumina 20 Years Ago Would Be Worth This Much Today | ||
| CRISPR THERAPEUTICS | 49,360 | -0,85 % | CRISPR Therapeutics legt positive Einjahresdaten für Gentherapie CTX310 vor | ||
| PALATIN TECHNOLOGIES | 10,500 | +0,19 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 1,162 | +1,57 % | Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,850 | +0,36 % | Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough? | ||
| NUREXONE BIOLOGIC | 0,349 | +4,18 % | Breaking News! NurExone Biologic plant großes Börsen-Upgrade! | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,242 | +3,11 % | PacBio Announces Second Quarter 2026 Financial Results | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent Business Highlights Total revenue of $39.0... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,660 | +1,20 % | RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation | The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most... ► Artikel lesen | |
| ATAIBECKLEY | 6,300 | 0,00 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen | |
| TWIST BIOSCIENCE | 125,15 | +2,54 % | Guggenheim bestätigt Rating für Twist Bioscience wegen Potenzial bei KI-Wirkstoffforschung | ||
| ONCO-INNOVATIONS | 0,340 | 0,00 % | Onco-Innovations Limited: Onco-Innovations Enters into LOI with Ifowonco for Exclusive Option and Worldwide Licence to LAG-3 Small-Molecule Inhibitor Program | CALGARY, AB / ACCESS Newswire / August 19, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered... ► Artikel lesen |
Das Unternehmen RENOVORX INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,670 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RENOVORX INC finden Sie auf Wallstreet Online.